Jay A. Cadieux, PhD, is vice-president of product development & operations; Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC, Canada.
Using Modified QbD to Develop a Novel Pediatric Formulation of Ezogabine
March 3rd 2021The epilepsy treatment, Potiga, has been used off-label to treat specific types of epilepsy in some children. However, it has never been formally evaluated in pediatric clinical trials. Using a modified QbD approach, the authors have developed a granular formulation suitable for use in clinical trials involving infants and children.